| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/1078-0432.CCR-11-2017 |
| P698 | PubMed publication ID | 22298894 |
| P2093 | author name string | Bruce E Johnson | |
| George W Sledge | |||
| David R Parkinson | |||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | biomarker | Q864574 |
| P304 | page(s) | 619-624 | |
| P577 | publication date | 2012-02-01 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | Making personalized cancer medicine a reality: challenges and opportunities in the development of biomarkers and companion diagnostics | |
| P478 | volume | 18 |
| Q56675475 | 'Toxgnostics': an unmet need in cancer medicine |
| Q42250997 | A rational free energy-based approach to understanding and targeting disease-causing missense mutations |
| Q38557650 | Applying nanomedicine in maladaptive inflammation and angiogenesis |
| Q38543009 | Cancer proteomics: developments in technology, clinical use and commercialization |
| Q36337004 | Cancer/testis antigens and urological malignancies |
| Q53870892 | Challenges in the codevelopment of companion diagnostics. |
| Q26999507 | Clinical application of genetics to guide prevention and treatment of oral diseases |
| Q92134487 | Computational Oncology in the Multi-Omics Era: State of the Art |
| Q35555483 | Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors |
| Q37551148 | From drug discovery to biomarker-driven clinical trials in lymphoma |
| Q33598001 | Genome-wide analysis of gynecologic cancer: The Cancer Genome Atlas in ovarian and endometrial cancer |
| Q28394818 | Getting personalized cancer genome analysis into the clinic: the challenges in bioinformatics |
| Q92840441 | High expression of LAMP1 as a prognostic marker in patients with epithelial ovarian cancer |
| Q35144956 | High expression of MAGE-A9 in tumor and stromal cells of non-small cell lung cancer was correlated with patient poor survival |
| Q28828601 | Identification of a long non-coding RNA NR_026689 associated with lung carcinogenesis induced by NNK |
| Q27303882 | Identifying potential indicators to measure the outcome of translational cancer research: a mixed methods approach |
| Q30242020 | Imaging biomarker roadmap for cancer studies |
| Q57052947 | Imaging tumour hypoxia with oxygen-enhanced MRI and BOLD MRI |
| Q38102920 | Implementing personalized cancer genomics in clinical trials |
| Q35067532 | Integrated next-generation sequencing and avatar mouse models for personalized cancer treatment |
| Q26992272 | Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity |
| Q37190679 | Next-generation companion diagnostics: promises, challenges, and solutions |
| Q34774908 | Next-generation sequencing in clinical oncology: next steps towards clinical validation |
| Q35852265 | Overexpression of MAGE-A9 Is Predictive of Poor Prognosis in Epithelial Ovarian Cancer |
| Q36591139 | Oxygen-Enhanced MRI Accurately Identifies, Quantifies, and Maps Tumor Hypoxia in Preclinical Cancer Models |
| Q45172832 | POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer |
| Q41022564 | Patient and Other Stakeholder Engagement in Patient-Centered Outcomes Research Institute Funded Studies of Patients with Kidney Diseases |
| Q35195408 | Personal genomes, quantitative dynamic omics and personalized medicine |
| Q40197692 | Pharmacogenomic biomarkers as inclusion criteria in clinical trials of oncology-targeted drugs: a mapping of ClinicalTrials.gov. |
| Q35997083 | Pilot Study of a Next-Generation Sequencing-Based Targeted Anticancer Therapy in Refractory Solid Tumors at a Korean Institution |
| Q31017820 | Precision medicine in the age of big data: The present and future role of large-scale unbiased sequencing in drug discovery and development |
| Q36653584 | Prognostic Value of KIF2A and HER2-Neu Overexpression in Patients With Epithelial Ovarian Cancer |
| Q38057179 | Therapeutic application of monoclonal antibodies in cancer: advances and challenges |
Search more.